循环肿瘤细胞（CTC）在非小细胞肺癌（NSCLC）中显示出重要的预后价值。然而，目前CTC捕获技术的低灵敏度限制了其临床应用。本研究旨在探讨将外周血细胞（PBC）衍生的基于炎症的评分与CTC相结合以提高CTC在NSCLC中的预后价值的可行性。招募了60名诊断为NSCLC的志愿者。检查了 CTC 计数和六项基于炎症的评分，并探讨了与无进展生存期 (PFS) 和总生存期 (OS) 的关联。观察免疫治疗前后CTC计数的变化。多因素分析显示CTC>7[风险比(HR)=9.07； 95% 置信区间 (CI)：3.68-22.37，P<0.001] 和单核细胞与淋巴细胞比率 (MLR) > 0.2（HR =3.07；95% CI：1.21-7.84；P=0.01）与较短的 OS 相关NSCLC 患者的 PFS 和 PFS。与CTC≤7且MLR≤0.2的患者相比，CTC>7且MLR>0.2的患者死亡风险增加12.30倍（P<0.001），疾病进展风险增加6.10倍（P=0.002）。免疫治疗后CTC计数下降与疾病控制密切相关（r=0.535，P=0.01）。CTC和MLR都是NSCLC患者预后的独立危险因素。 CTC与MLR的结合显着提高了CTC的预后价值，这将有助于NSCLC患者的分层并提供精确的治疗。 CTC 的动态监测有效显示 NSCLC 中的免疫治疗反应。2024 转化癌症研究。版权所有。

Circulating tumor cells (CTCs) has shown important prognostic value in non-small cell lung cancer (NSCLC). However, the present low sensitivity of CTC capture technology restricts their clinical application. This study aims to explore the feasibility of combining the peripheral blood cell (PBC)-derived inflammation-based score with CTCs to increase the prognostic value of CTCs in NSCLC.Sixty volunteers diagnosed with NSCLC were recruited. CTC count and six inflammation-based scores were examined and the association with progression-free survival (PFS) and overall survival (OS) was explored. The changes in the CTC counts before and after the immunotherapy were observed.Multivariate analysis showed that CTCs >7 [hazard ratio (HR) =9.07; 95% confidence interval (CI): 3.68-22.37, P<0.001] and monocytes-to-lymphocytes ratio (MLR) > 0.2 (HR =3.07; 95% CI: 1.21-7.84; P=0.01) were associated with shorter OS and PFS in patients with NSCLC. Patients with CTCs >7 and MLR >0.2 had 12.30 times increased risk of death (P<0.001) and 6.10 times increased risk of disease progression (P=0.002) compared with those with CTCs ≤7 and MLR ≤0.2. Decreased CTC counts after immunotherapy were closely related to disease control (r=0.535, P=0.01).CTCs and MLR are both independent risk factors for prognosis in patients with NSCLC. The combination of CTCs with MLR significantly increased the prognostic value of CTCs, which would contribute to stratification of NSCLC patients and providing precise treatment. Dynamic monitoring of CTCs efficiently shows the immunotherapy response in NSCLC.2024 Translational Cancer Research. All rights reserved.